

JEEVAN SCIENTIFIC TECHNOLOGY LIMITED  
Registered Office: Plot No. 1 & 2, Sai Krupa Enclave, Manikonda Jagir, Near Lanco Hills, Hyderabad-500008.  
CONSOLIDATED UN AUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED 31ST DECEMBER, 2019

Sl.No	Particulars	Rupees in Lakhs					
		Quarter Ended			Nine Months Ended		Previous Year Ended
		31-12-2019 Un Audited	30-09-2019 Un Audited	31-12-2018 Un Audited	31-12-2019 Un Audited	31-12-2018 Un Audited	31-03-2019 Audited
1	Income						
	(a) Revenue From Operations	842.69	526.40	800.43	1686.40	2,178.56	2,612.77
	(b) Other Income	37.7	28.81	11.12	92.09	89.93	97.14
	<b>Total income</b>	<b>880.39</b>	<b>555.21</b>	<b>811.55</b>	<b>1,778.49</b>	<b>2,268.49</b>	<b>2,709.91</b>
2	Expenses						
	(a) Cost of Material Consumed	40.97	38.98	59.75	117.73	138.76	164.18
	(b) Purchase of stock-in-trade	-	-	-	-	-	-
	(c) Changes in Inventories of finished goods, work-in-progress and stock-in-trade	-	-	-	-	-	-
	(d) Employee benefit expense	293.17	240.55	236.66	750.78	637.82	835.56
	(e) Finance Cost	73.85	68.95	56.27	203.82	154.73	190.08
	(f) Depreciation and Amortisation expense	100.1	99.99	89.12	298.69	242.77	313.16
	(g) Other Expenses	310.69	278.57	251.50	785.28	795.05	1,070.38
	<b>Total Expenses</b>	<b>818.78</b>	<b>727.04</b>	<b>693.30</b>	<b>2,156.30</b>	<b>1,969.13</b>	<b>2,573.36</b>
3	Profit before exceptional items and Tax	61.61	-171.83	118.25	-377.81	299.36	136.55
4	Add(+)/Less(-) Exceptional items	-	-	-	-	-	-
5	Profit before Tax	61.61	-171.83	118.25	-377.81	299.36	136.55
6	Tax Expenses	-23.05	34.53	38.36	68.99	38.56	25.15
7	Profit(Loss) for the Period from Continuing Operations	38.56	-137.30	79.89	-308.82	260.80	111.40
8	Profit(Loss) from Discontinuing Operations	-	-	-	-	-	-
9	Tax Expenses on discontinuing Operations	-	-	-	-	-	-




*[Handwritten signature]*

Sl.No	Particulars	Quarter Ended			Nine Months Ended		Previous Year Ended
		31-12-2019	30-09-2019	31-12-2018	31-12-2019	31-12-2018	31-03-2019
		Un Audited	Un Audited	Un Audited	Un Audited	Un Audited	Audited
10	Profit(Loss) from Discontinuing Operations after Tax	-	-	-	-	-	-
11	Profit(Loss) for the period	38.56	-137.30	79.89	-308.82	260.80	111.40
12	Other Comprehensive Income						
	A (i) Items that will not be reclassified to profit or loss	0.98	-8.09	0.25	-6.77	0.75	1.94
	(ii) Income tax relating to items that will not be reclassified to profit or loss	-	-	-0.11	-	-0.21	-0.54
	B (i) Items that will be reclassified to profit or loss	-	-	-	-	-	-
	(ii) Income tax relating to items that will be reclassified to profit or loss	-	-	-	-	-	-
13	Total Comprehensive Income for the period	39.54	-145.39	80.03	-315.59	261.34	112.80
14	Paid Up Equity Share Capital (Face Value of Rs.10/- each)	1,530.15	1,530.15	1,530.15	1,530.15	1,530.15	1,530.15
15	Other equity excluding revaluation reserve						1,653.17
16	Earnings per Equity share ( for continuing operations)						
	a) Basic (Amount in Rupees)	0.26	-0.95	0.52	-2.06	1.71	0.74
	b) Diluted (Amount in Rupees)	0.26	-0.95	0.52	-2.06	1.83	0.78
17	Earnings per Equity share ( for discontinued operations)						
	a) Basic (Amount in Rupees)				-	-	-
	b) Diluted (Amount in Rupees)				-	-	-
18	Earnings per Equity share ( for Continuing & discontinued operations)						
	a) Basic (Amount in Rupees)	0.26	-0.95	0.52	-2.06	1.71	0.74
	b) Diluted (Amount in Rupees)	0.26	-0.95	0.52	-2.06	1.83	0.78

#### Notes to the Consolidated Un Audited Financial Results

- The above financial results are prepared in accordance with IND AS notified under the Company (Indian Accounting Standards) Rules, 2015
- The above results have been reviewed by the Audit Committee at its meeting held on 14.02.2020 and approved by the Board of Directors of the Company on the same date. These Results are also subjected to Limited Review by the Company's Statutory Auditors.
- The Group currently has two segments (i) clinical research services and (ii) Information technology services.
- The Group has adopted Ind As-116, effective annual reporting period beginning April 1, 2019 and applied the standard to its leases. However, there is no impact on the financials of the company.
- Figures for the previous periods have been rearranged wherever necessary.
- The above consolidated financial results include the Un Audited financial results of the wholly owned subsidiaries, M/s Enhops Solutions Pvt Ltd & Enhops Inc.

Place:Hyderabad  
Date:14.02.2020



SEGMENT-WISE REVENUE, RESULTS & CAPITAL EMPLOYED ( Consolidated Unaudited )  
UNDER CLAUSE 41 OF THE LISTING AGREEMENT FOR THE QUARTER ENDED 31ST DECEMBER, 2019

Particulars	Rupees in Lakhs					
	Quarter Ended			Nine Months Ended		Previous Year Ended
	31-12-2019 Un Audited	30-09-2019 Un Audited	31-12-2018 Un Audited	31-12-2019 Un Audited	31-12-2018 Un Audited	31-03-2019 Audited
<b>SEGMENT REVENUE: (Net Sales / Income from Operations)</b>						
a) Clinical Research Services	763.87	510.79	783.25	1591.04	2,120.40	2,636.87
b) Information Technology Services	116.52	44.42	17.18	187.45	58.16	73.04
c) Data Management Services	-	-	-	-	-	-
d) Unallocable income	-	-	11.12	-	89.93	-
Total:	880.39	555.21	811.55	1,778.49	2,268.49	2,709.91
LESS: Inter Segment revenue	-	-	-	-	-	-
Net Sales/ income from Operations.	880.39	555.21	811.55	1,778.49	2,268.49	2,709.91
<b>SEGMENT RESULTS : PROFIT / (LOSS) BEFORE TAX AND INTEREST</b>						
a) Clinical Research Services	131.66	-102.77	164.73	-174.92	363.49	333.12
b) Information Technology Services	3.80	-0.11	-1.33	0.93	0.67	-5.22
c) Data Management Services	-	-	-	-	-	-
Total:	135.46	-102.88	163.40	-173.99	364.16	327.90
LESS:						
i) Interest	73.85	68.95	56.27	203.82	154.73	190.08
ii) Other Un-Allocable Expenditure	-	-	-	-	-	1.27
iii) Un-Allocable Income	-	-	-11.12	-	-89.93	-
<b>TOTAL PROFIT /(-LOSS) BEFORE TAX</b>	<b>61.61</b>	<b>-171.83</b>	<b>118.25</b>	<b>-377.81</b>	<b>299.36</b>	<b>136.55</b>

Place:Hyderabad  
Date: 14.02.2020

for Jeevan Scientific Technology Limited  
On behalf of the Board of Directors

K. Krishna Kishore  
Vice Chairman & Managing Director

